Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.61 |
| ▸ | MAOB | P27338 | 3/20 | 0.60 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16535779 | 1.00 | LIPG (0.61) | LIPGMAOBCNR1CNR2NPC1 | |
| SCHEMBL16535755 | 0.80 | LIPG (0.52) | LIPGMAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16535751 | 0.80 | LIPG (0.52) | LIPGMAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19701364 | 0.79 | MAOB (0.76) | MAOBCNR1CNR2NPC1RAB9A | |
| SCHEMBL21490032 | 0.79 | MAOB (0.76) | MAOBCNR1CNR2NPC1RAB9A | |
| SCHEMBL16535386 | 0.78 | LIPG (0.78) | LIPGNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL16535388 | 0.78 | LIPG (0.78) | LIPGNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6084702 | 0.77 | MAOB (0.76) | MAOBCNR1CNR2NPC1RAB9A | |
| SCHEMBL6084707 | 0.77 | MAOB (0.76) | MAOBCNR1CNR2NPC1RAB9A | |
| SCHEMBL28932676 | 0.76 | MAOB (1.00) | MAOBCNR1CNR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844643-B1 | PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9199946-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150065505-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065505-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, PNLIP | LIPG 1/4885MAOB 387/4885CNR1 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.